Therapeutic Candidate Articles & Analysis
122 news found
By leveraging a suite of biomimetic and AI-powered technologies, BBBporter™ enables the efficient transport of therapeutic candidates into the brain, opening new avenues for preclinical drug development in areas such as Alzheimer's disease, Parkinson's disease, stroke, and epilepsy. ...
Ace Therapeutics, a preclinical contract research provider dedicated to offering comprehensive one-stop services, released the expansion of its research capabilities in the area of depression through the introduction of comprehensive depression-related behavior tests in its preclinical investigation processes. This integral development aims to enhance the understanding of ...
A recent breakthrough in PAH research by Studley et al (2024) introduces compound 17b, a small-molecule biased agonist of formyl peptide receptors (FPRs), as a novel and promising therapeutic candidate. This compound has demonstrated a unique ability to combine vasodilation with anti-inflammatory effects, tackling two major drivers of the disease simultaneously. ...
Anastasia Komarova, director of the joint laboratory, has shown that modified viruses from the measles platform generate large quantities of these DI-RNAs, which could constitute a new generation of innovative therapeutic candidates. Isabelle Buckle, Director of Research Applications and Industrial Relations at the Institut Pasteur, said: “The creation of ...
ByOncoVITA
” Jack Syage, PhD and CEO of ImmunogenX, states, “We are excited by the continued success of latiglutenase as a leading therapeutic candidate for celiac disease patients as an adjunct to a gluten-free diet. ...
Airfinity announces today the launch of Airfinity IDA (Infectious Disease Analytics) 360, a new platform that will provide a comprehensive overview of vaccine and therapeutics candidates across the full infectious disease landscape. Airfinity IDA 360, a first-of-its-kind product in the health analytics market, will be a centralised source of competitive ...
(NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. ...
About Lumos Pharma Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a ...
(NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the Piper Sandler 34th Annual Healthcare Conference November 29th through December 1st. ...
Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announced today that it has raised $41 million in an oversubscribed Series A, bringing its total funding to $50 million. ...
Proceeds and cost-savings from the divestiture of the CDMO facility and reduction in operations will be invested in advancing the Company’s lead immuno-oncology assets towards the clinic, as well as the continued development of the RubrYc® Discovery Engine, the artificial intelligence (“AI”) platform used to create the majority of iBio’s therapeutic ...
“Our partnership with Ray Therapeutics showcases how these new offerings can accelerate AAV gene therapies from idea into reality for patients in need, and we are excited to help Ray Therapeutics meet the needs of patients with retinitis ...
iBio is jockeying for position as a leading player in Al-powered drug discovery while also expanding its immuno-oncology pipeline after closing on the acquisition of multiple assets from its partner, RubrYc Therapeutics. The plant-based drug developer and contract development and manufacturing organization (CDMO) said the deal shores up its ambition to bring immunotherapies to ...
(NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that Lumos Pharma management will participate in a panel discussion and host one-on-one meetings at the Cantor Neurology & Psychiatry Conference in October. ...
The CDMO outfit iBio has netted a deal that sees it gain access to an AI-based platform as well as new therapeutic candidates as it looks to dive further into drug discovery. iBio closed on acquiring several assets from the San Diego-based biotech RubrYc Therapeutics, snapping up several oncology programs. The cost includes a $1 million upfront ...
Previously Licensed Candidates: All rights – with no future milestone payments or royalty obligations – to two molecules. These include IBIO-101, an IL-2 sparing anti-CD25 antibody for depletion of regulatory T cells, as well as “Target 6” that was discovered in Q2 FY2022 using the Discovery Engine. New Therapeutic ...
(Nasdaq: ALNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) announced today preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatitis (NASH). ...
(“The Company,” NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), today announced that its board of directors has authorized a share repurchase program to acquire up to $3 million of the Company’s common stock. ...
This program is an allogeneic, or donor-derived, gamma-delta T cell therapeutic candidate in development for patients with high-risk leukemias undergoing haploidentical hematopoietic stem cell transplant (HSCT). ...
(“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the first patient has been dosed in a Phase 1 study of an investigational candidate resulting from the collaboration between Sutro and Merck, known as MSD outside the United States and ...